99mTc-NM-02
Radiotoxicity
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Radiotoxicity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM IRCCS San Raffaele | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Sun Yat-sen University | Phase 3 | BB |
Amifostine Alliance for Clinical Trials in Oncology | Phase 3 | BB |
ETOPOSIDE Sun Yat-sen University | Phase 3 | BB |
Carboplatin Sun Yat-sen University | Phase 3 | BB |
View all 37 →
Same molecule, other indications
99mTc-NM-02 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →